At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 606 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Alopecia Areata. Completed, enrolled 606 participants across 96 sites in 10 countries.
Detailed Summary
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesArgentina, Australia, Brazil, China, Israel, Japan, Puerto Rico, South Korea, Taiwan, United States
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJul 2019
Primary CompletionJan 2021
Study CompletionNov 2024
TodayJul 2026
First PostedApr 2, 2019
Enrollment StartJul 8, 2019
Primary CompletionJan 24, 2021
Study CompletionNov 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.3 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally